A Multi-center, Open-label, Non-controlled Study to Evaluate the Safety, Efficacy and Pharmacokinetics of TMX-67 after Oral Administration in Hyperuricemic Pediatric Patients with or without Gout (Extension Study)

In pediatric patients with hyperuricemia including gout, safety, efficacy, and pharmacokinetics of 52-week multiple oral doses of TMX-67 were investigated in an open-label and uncontrolled design. As a result, serum uric acid decreased with increase of TMX-67 dose and maintained serum uric acid of <= 6.0 mg/dL or around 6.0 mg/dL for a long term until Week 52. No significant concern was identified for long-term safety until Week 52.